Serum cystatin C level, kidney disease markers, and incidence of age-related macular degeneration: The beaver dam eye study

Archives of Ophthalmology

Volumn 127, Issue 2, 2009, Pages 193-199

  Klein, Ronald ^a   Knudtson, Michael D ^a   Lee, Kristine E ^a   Klein, Barbara E K ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C; NITROGEN; UREA; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; UREA NITROGEN BLOOD LEVEL; UVEITIS; BLOOD; CHRONIC KIDNEY FAILURE; DISEASE COURSE; GLOMERULUS FILTRATION RATE; MIDDLE AGED; RETINA MACULA DEGENERATION; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD UREA NITROGEN; CYSTATIN C; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROTEINURIA; RISK FACTORS; WISCONSIN;

EID: 60549101748     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2008.551     Document Type: Article

References (61)

1. Dragon-Durey MA, Frémeaux-Bacchi V, LoiratC, etal. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or mem-branoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol. 2004;15(3):787-795.
2. Abrera-Abeleda MA, Nishimura C, Smith JL, et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet. 2006;43(7):582-589.
3. Ying L, Katz Y, Schlesinger M, et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet. 1999;65(6):1538-1546.
4. Buddles MR, Donne RL, Richards A, Goodship J, Goodship TH. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet. 2000;66(5):1721-1722.
5. Pérez-Caballero D, González-Rubio C, Gallardo ME, et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet. 2001;68(2):478-484.
6. Alexander JJ, Pickering MC, Haas M, Osawe I, Quigg RJ. Complement factor h limits immune complex deposition and prevents inflammation and scarring in glomeruli of mice with chronic serum sickness. J Am Soc Nephrol. 2005;16 (1):52-57.
7. Alexander JJ, Wang Y, Chang A, et al. Mouse podocyte complement factor H:the functional analog to human complement receptor 1. J Am Soc Nephrol. 2007;18(4):1157-1166.
8. Saunders RE, Goodship TH, Zipfel PF, Perkins SJ. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. Hum Mutat. 2006;27(1):21-30.
9. Tsukaguchi H, Yager H, Dawborn J, et al. A locus for adolescent and adult onset familial focal segmental glomerulosclerosis on chromosome 1q25-31. J AmSoc Nephrol. 2000;11(9):1674-1680.
10. Vollmer M, Jung M, Rüschendorf F, et al. The gene for human fibronectin glomerulopathy maps to 1q32, in the region of the regulation of complement activation gene cluster. Am J Hum Genet. 1998;63(6):1724-1731.
11. Cohn DH, Shohat T, Yahav M, et al. A locus for an autosomal dominant form of progressive renal failure and hypertension at chromosome 1q21. Am J Hum Genet. 2000;67(3):647-651.
12. Caprioli J, Castelletti F, Bucchioni S, et al; International Registry of Recurrent and Familial HUS/TTP. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet. 2003;12(24):3385-3395.
13. Neumann HP, Salzmann M, Bohnert-Iwan B, et al. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet. 2003;40(9):676-681.
14. Neary JJ, Conlon PJ, Croke D, et al. Linkage of a gene causing familial mem-branoproliferative glomerulonephritis type III to chromosome 1. J Am Soc Nephrol.2002;13(8):2052-2057.
15. Fox CS, Yang Q, Cupples LA, et al. Genomewide linkage analysis to serum cre-atinine, GFR, and creatinine clearance in a community-based population: the Framingham Heart Study. J Am Soc Nephrol. 2004;15(9):2457-2461.
16. Thompson CL, Klein BE, Klein R, et al. Complement factor H and hemicentin-1 in age-related macular degeneration and renal phenotypes. Hum Mol Genet. 2007;16(17):2135-2148.
17. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65(3):1009-1016.
18. Mezzano D, Pais EO, Aranda E, et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int. 2001;60(5):1844-1850.
19. Landray MJ, Wheeler DC, Lip GY, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the Chronic Renal Impairment in Birmingham (CRIB) Study. Am J Kidney Dis. 2004;43(2):244-253.
20. Decanini A, Nordgaard CL, Feng X, Ferrington DA, Olsen TW. Changes in select redox proteins of the retinal pigment epithelium in age-related macular degeneration. Am J Ophthalmol. 2007;143(4):607-615.
21. Tsao YP, HoTC, Chen SL, Cheng HC. Pigmentepithelium-derived factor inhibits oxidative stress-induced cell death by activation of extracellular signal-regulated kinases in cultured retinal pigment epithelial cells. Life Sci. 2006;79(6):545-550.
22. Pow DV, Sullivan RK, Williams SM, WoldeMussie E. Transporters and oxidative stress in AMD. In: Penfold PL, Provis JM, eds. Macular Degeneration. New York, NY: Springer-Verlag; 2005:123-148.
23. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20(6):705-732.
24. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134 (3):411-431.
25. Klein R, Klein BE, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology. 1999;106(6):1056-1065.
26. Blumenkranz MS, Russell SR, Robey MG, Kott-Blumenkranz R, Penneys N. Risk factors in age-related maculopathy complicated by choroidal neovascularization. Ophthalmology. 1986;93(5):552-558.
27. Liew G, Mitchell P, Wong TY, Iyengar SK, Wang JJ. CKD increases the risk of age-related macular degeneration. J Am Soc Nephrol. 2008;19(4):806-811.
28. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C, Grubb A. Cystatin C as a marker of GFR: history, indications, and future research. Clin Biochem. 2005;38(1):1-8.
29. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impacton renal function measurement. Kidney Int. 2004;65(4):1416-1421.
30. Wasselius J, Hakansson K, Johansson K, Abrahamson M, Ehinger B. Identification and localization of retinal cystatin C. Invest Ophthalmol Vis Sci. 2001;42 (8):1901-1906.
31. BarkaT, van der Noen H. Expression of the cysteine proteinase inhibitor cystatin C mRNA in rat eye. Anat Rec. 1994;239(3):343-348.
32. Linton KL, Klein BE, Klein R. The validity of self-reported and surrogate-reported cataract and age-related macular degeneration in the Beaver Dam Eye Study. Am J Epidemiol. 1991;134(12):1438-1446.
33. Klein R, Klein BE, Linton KL, De Mets DL.The Beaver Dam Eye Study: visual acuity. Ophthalmology. 1991;98(8):1310-1315.
34. Klein R, Klein BE, Lee KE. Changes in visual acuity in a population: the Beaver Dam Eye Study. Ophthalmology. 1996;103(8):1169-1178.
35. Klein R, Klein BE, Lee KE, Cruickshanks KJ, Chappell RJ. Changes in visual acuity in a population over a 10-year period: the Beaver Dam Eye Study. Ophthalmology. 2001;108(10):1757-1766.
36. Klein R, Klein BE, Lee KE, Cruickshanks KJ, Gangnon RE. Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol. 2006;142(4):539-549.
37. Klein R, Klein BE. The Beaver Dam Eye Study II: Manual of Operations. Springfield, VA: US Dept of Commerce; 1995. NTIS Accession No. PB95-B273827.
38. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98(7):1128-1134.
39. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin Age-Related Maculopathy Grading System. Springfield, VA: US Dept of Commerce;1991. NTIS Accession No. PB91-B184267.
40. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99(6):933-943.
41. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997;104(1):7-21.
42. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2002;109(10):1767-1779.
43. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114(2):253-262.
44. Klein R, Klein BE, Moss SE. Relation of smoking to the incidence of age-related maculopathy: the Beaver Dam Eye Study. Am J Epidemiol. 1998;147(2):103-110.
45. Klein R, Klein BE. The Beaver Dam Eye Study III: Manual of Operations. Springfield, VA: US Dept of Commerce; 1999. NTIS Accession No. PB99-B137861.
46. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461-470.
47. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2)(suppl 1):S1-S266.
48. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons, Inc; 1989:238-245.
49. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JAm StatAssoc. 1958;53(282):457-481. doi:10.2307/2281868.
50. Abrahamson M, Barrett AJ, Salvesen G, Grubb A. Isolation of six cysteine pro-teinase inhibitors from human urine: their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J BiolChem. 1986;261(24):11282-11289.
51. Barrett AJ. The cystatins: a diverse superfamily of cysteine peptidase inhibitors.Biomed Biochim Acta. 1986;45(11-12):1363-1374.
52. Turk V, Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 1991;285(2):213-219.
53. Abrahamson M. Cystatins. Methods Enzymol. 1994;244:685-700.
54. Paraoan L, Grierson I, Maden BE. Fate of cystatin C lacking the leadersequence in RPE cells. Exp Eye Res. 2003;76(6):753-756.
55. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000; 486(3):247-251.
56. Zatterstrom UK, Felbor U, Fukai N, Olsen BR. Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struct Funct. 2000;25(2):97-101.
57. Marneros AG, Keene DR, Hansen U, et al. Collagen XVIII/endostatin is essential forvision and retinal pigment epithelial function. EMBOJ. 2004;23(1):89-99.
58. Im E, Venkatakrishnan A, Kazlauskas A. Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell. 2005;16(8):3488-3500.
59. Zurdel J, Finckh U, MenzerG, Nitsch RM, Richard G. CST3 genotype associated with exudative age related macular degeneration. Br J Ophthalmol. 2002;86 (2):214-219.
60. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
61. Knudtson MD, Klein BE, Klein R. Age-related eye disease, visual impairment, and survival: the Beaver Dam Eye Study. Arch Ophthalmol. 2006;124(2):243-249.